Vernalis completes first patient dosing in PD drug trial
The trial, which will be conducted in healthy male volunteers, is a combined single and multiple ascending dose safety, tolerability and pharmacokinetic trial. The company expects to evaluate
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.